MedTrace Logo

Cancer Genome Atlas of China:Lung Cancer

NCT04266483 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2020-02-17

No results posted yet for this study

Summary

Based on 2500 lung cancer tumor tissue samples from about 40 clinical centers in China, the molecular typing of lung cancer in China will be figured out by high throughput sequencing, which will provide the basis for the follow-up research and development of new drugs as well as the guidance of treatment.

Conditions

Sponsors & Collaborators

  • ChosenMed Technology (Beijing) Co.,Ltd

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Xiuyi Zhi, M.D. · Xuanwu Hospital, Beijing

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-08
Primary Completion
2022-11-08
Completion
2022-11-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04266483 on ClinicalTrials.gov